FDA puts partial hold on CytRx cancer drug trials

(Reuters) – CytRx Corp said the U.S. Food and Drug Administration placed a hold on enrolling new patients in clinical trials of its experimental cancer drug after a patient died, sending the company’s shares down 11 percent in premarket trading. The patient received the drug, aldoxorubicin, under the company’s expanded access program that makes promising drugs and devices available to patients with serious diseases who do not qualify for the trials. Patients already enrolled in the trials, currently in mid stage, will continue receiving the treatment, CytRx said. …
Go to Source